Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 3/20 | 0.76 |
| ▸ | COMT | P21964 | 2/20 | 0.52 |
| ▸ | HTR6 | P50406 | 4/20 | 0.48 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3889418 | 0.87 | MET (1.00) | METHTR6CDC7KMT2AAXL | |
| SCHEMBL28094884 | 0.86 | MET (0.76) | METCOMTKMT2AAXLMEN1 | |
| SCHEMBL30286786 | 0.81 | MET (0.53) | METCDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL21545936 | 0.81 | MET (0.53) | METCDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL27538994 | 0.80 | MET (0.52) | METCOMTCDC7ROCK2MAP4K4 | |
| SCHEMBL28315134 | 0.75 | MET (0.65) | METCDK2KMT2AAXLGPR84 | |
| SCHEMBL29385908 | 0.75 | MET (0.65) | METCDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL30286312 | 0.75 | MET (0.65) | METCDK2KMT2AAXLGPR84 | |
| SCHEMBL15064398 | 0.75 | MET (0.65) | METCDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL859112 | 0.75 | GPR84 (0.51) | METCDC7CDK2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585873-B2 | antiserotonine agents; central nervous system disorders; Alzheimer's disease; 3-(Phenylthio)-1H-pyrrolo[2,3-b]pyridine | WYETH (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585873-B2 | antiserotonine agents; central nervous system disorders; Alzheimer's disease; 3-(Phenylthio)-1H-pyrrolo[2,3-b]pyridine | WYETH (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1509522-B1 | 1-(AMINOALKYL)-3-SULFONYLAZAINDOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1509522-B1 | 1-(AMINOALKYL)-3-SULFONYLAZAINDOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2007-02-28 | — | — | EP | disclosed |
| US-7074792-B2 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-07-11 | — | — | US | disclosed |
| US-20060148831-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-07-06 | — | — | US | disclosed |
| US-20050085481-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-04-21 | — | — | US | disclosed |
| EP-1509522-A1 | 1-(AMINOALKYL)-3-SULFONYLAZAINDOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth, A Corporation of the State of Delaware (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6825212-B2 | SEROTONINE RECEPTORS ANTAGONIST; CENTRAL NERVOUS SYSTEM DISORDERS | WYETH | 2004-11-30 | — | — | US | disclosed |
| US-20030236278-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-12-25 | — | — | US | disclosed |
| WO-2003101990-A1 | 1-(AMINOALKYL)-3-SULFONYLAZAINDOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148831-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR1A | MET 1096/4885COMT 674/4885HTR6 1/4885 |
| US-20050085481-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR1A | MET 1096/4885COMT 674/4885HTR6 1/4885 |
| US-20030236278-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR1A, HTR3B | MET 1033/4885COMT 686/4885HTR6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.